Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy

@inproceedings{Sengupta2012ImpactOT,
  title={Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy},
  author={Sadhak Sengupta and Jaclyn Marrinan and Caroline Frishman and Prakash Sampath},
  booktitle={Clinical & developmental immunology},
  year={2012}
}
Malignant glioma, or glioblastoma, is the most common and lethal form of brain tumor with a median survival time of 15 months. The established therapeutic regimen includes a tripartite therapy of surgical resection followed by radiation and temozolomide (TMZ) chemotherapy, concurrently with radiation and then as an adjuvant. TMZ, a DNA alkylating agent, is the most successful antiglioma drug and has added several months to the life expectancy of malignant glioma patients. However, TMZ is also… CONTINUE READING
36 Citations
82 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 82 references

Similar Papers

Loading similar papers…